Erschienen in:
01.05.2007 | Original Paper
The Beneficial Effect of Aspirin and Enoxaparin on Fibrosis Progression and Regenerative Activity in a Rat Model of Cirrhosis
verfasst von:
Nimer Assy, Osamah Hussein, Abdallah Khalil, Anthony Luder, Sergio Szvalb, Melia Paizi, Gadi Spira
Erschienen in:
Digestive Diseases and Sciences
|
Ausgabe 5/2007
Einloggen, um Zugang zu erhalten
Abstract
The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy. Thioacetamide-induced cirrhotic rats received saline (N=10), aspirin (N=7), or enoxaparin (N=11) for a 5-week treatment period. Hepatic fibrosis was assessed according to METAVIR score. Liver regeneration was monitored using PCNA immunostaining. Compared to untreated cirrhotic controls, a significant improvement in fibrosis grade was observed in the aspirin (43%; χ2=54, P < 0.001) and enoxaparin (36%; χ2=43, P < 0.001) treated groups. Postoperatively, total serum bilirubin levels were lower in the aspirin (1.4±0.18 mg/dl; P < 0.01) and enoxaparin (1.8±0.35 mg/dl; P < 0.05)-treated groups compared to untreated cirrhotic controls (3.2±0.6 mg/dl). Hepatic regenerative activity was significantly improved in the aspirin group (57.3%±6.8%, versus 34.2%±7.2% in untreated cirrhotic controls; P < 0.01) but unchanged in the enoxaparin group. We conclude that aspirin and enoxaparin hold promise as a useful therapy for patients with extensive fibrosis.